Cancer patients receiving certain chemotherapy agents have an increased risk of developing cardiovascular complications, and the risk is even greater if there is a known history of heart disease. Among the serious clinical cardiac complications that have been reported are arrhythmias, myocardial necrosis causing a dilated cardiomyopathy, and vasoocclusion or vasospasm resulting in angina or myocardial infarction. Chemotherapy agents can cause cardiotoxicity by a variety of mechanisms. The anthracyclines and related compounds (doxorubicin,daunorubicin, idarubicin, epirubicin, and the anthracenedione mitoxantrone) are the most frequently implicated agents and can cause an irreversible and sometimes fatal cardiomyopathy.This article is focus on a prostate cancer patient who received mitoxantrone therapy with an accumulative dose higher than usual recommended maximum dose and deid from congestive heart failure associated with mitoxantrone. And, in order to decrease the incidence of drug-induced congestive heart failure, it is recommended that left ventricular ejection fraction (LVEF) should be performed prior to initiation of therapy and do not administer mitoxantrone to patients with LVEF less than 50%, with a clinically significant reduction in LVEF, or to those with a cumulative lifetime dose of 140 mg/m2 or higher. Evaluations should be performed by echocardiogram or multi-gated radionuclide angiography. Monitoring of cardiac function including symptoms of congestive heart failure or cardiac arrhythmias prior to initiating therapy and during therapy is suggested.